Table 1.
Selected neoadjuvant chemotherapy studies.
| Study Design | Regimen | No of Patients | pCR (%) | Median OS (months) | Survival Benefit | Author | Year |
|---|---|---|---|---|---|---|---|
| Phase III RCT177 | Cisplatin | 62 | 19.6 | 34.2 in Cisplatin arm 23.1 in Control arm |
No | Martinez- Pireiro | 1995 |
| Phase III RCT10 | MVAC | 153 | 38 | 77 in MVAC arm 46 in Control arm |
Yes | Grossman | 2003 |
| Phase III RCT178 | CMV | 491 | 32.5 | 44 in CMV arm 37 in Control arm |
Yes | MRC/EORTC | 2011 |
| Phase II61 | PCaG Arm 1(T2-3N0) Arm 2 (T4 or N+) |
22 29 |
32 21 |
18.8 28.5 |
Smith | 2008 | |
| Phase II179 | GC | 15 | 26.7 | 36 | Herchenhorn | 2007 | |
| Phase II180 | ddDVAC + bevacizumab | 44 | 39 | Not yet reached | Siefker-Radtke | 2011 | |
| Phase II181 | ddDVAC | 44 | 36.1 | Plimack | 2012 | ||
| Retrospective182 | GC | 25 | 20 | Scosyrev | 2012 | ||
| Retrospective51 | GC MVAC |
42 54 |
26.2 28 |
Dash | 2008 | ||
| Retrospective183 | GC MVAC |
22 9 |
50 22.2 |
Kaneko | 2011 | ||
| Retrospective50 | GC MVAC |
37 77 |
25 31 |
Yeshchina | 2012 | ||
| Retrospective184 | GC MVAC |
24 22 |
25 22.5 |
35.3 | Pal | 2012 |
RCT = randomized controlled trial; GC = gemcitabine and cisplatin; MVAC = methotrexate, vinblastine, doxorubicin, and cisplatin; PCaG = paclitaxel, carboplatin, and gemcitabine; CMV = cisplatin, methotrexate, and vinblastine; ddDVAC = dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin.